Skip to main content
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Digital Health
    • Transformation
    • ESG
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Opinion
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Hospital at Home
    • - Workplace of the Future
    • - Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • Data Center
    • Data Center Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • Newsletters
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Providers
October 05, 2013 01:00 AM

New drugs carry hefty price tags

Makers of leading-edge orphan products asked to cut prices, take smaller profits

Jaimy Lee
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print

    The market for drug therapies for rare diseases is becoming increasingly crowded with expensive new products, a Modern Healthcare review of FDA approval and company pricing data shows.

    Most of the new orphan drugs cost more than $7,500 a month, which has prompted some experts to call on drugmakers to reduce prices and take smaller profits.

    Two drugs approved by the Food and Drug Administration during the past year treat a rare type of high cholesterol called homozygous familial hypercholesterolemia, a genetic disorder that affects one in a million people. Aegerion's Juxtapid was approved in December and costs $295,000 a year. Genzyme's Kynamro, which was approved a month later, is less expensive but still one of the priciest drugs to come to market during the FDA's fiscal 2013, which ended Sept. 30. It costs roughly $162,600 a year.

    All nine new oncology drugs approved in 2013 cost more than $5,500 a month. Three of the treatments were also approved with companion diagnostics, which have separate costs associated with genetic testing.

    “I don't see (prices) going down,” said Joshua Cohen, research assistant professor at the Tufts Center for the Study of Drug Development. “There's still a lot of unmet needs.”

    The drugs reflect the industry's ongoing focus on the orphan-drug market, one of the biggest growth areas for drug approvals. One-third of the 30 new molecular entities and new therapeutic biological products approved by the FDA last year are orphan drugs.

    More than half the newly approved orphan drugs received standard review by the FDA. Drugs that receive priority review are considered “major advances in treatment, or provide a treatment where no adequate therapy exists,” according to the FDA.

    Drug companies and physicians say better science is leading to more targeted therapies and new treatments. But the patients and insurers responsible for covering the drugs' costs face new challenges in their efforts to get the best treatment at the lowest cost. “We're going to see pushback from payers and hospitals,” Cohen said.

    Unlike in some European countries, where the national health systems have said they will not cover the costs of certain drugs, U.S. payers generally are unwilling to deny coverage. Competition with other private insurers and pressure from elected officials and patient groups—some of which receive funding from drug companies—make out-and-out denial difficult even if the science doesn't stack up.

    “The divided private market makes that kind of pushback harder,” said Dr. Aaron Kesselheim, assistant professor of medicine at Harvard Medical School.

    Payers are using higher patient cost-sharing as one strategy to limit their costs. Tufts researchers found that the coinsurance rate for biologics has doubled to about 30% over the past decade. Prior authorization, quantity limits and step therapy—a policy that requires patients to first try a less costly drug—are other examples of payer pushback.

    “As new therapies are developed for limited patient populations based on individual genetic variants, the market for each product will become smaller and smaller; accordingly, prices may become higher and higher,” Dr. Brian O'Sullivan, a pediatric pulmonologist, wrote Oct. 2 in the Journal of the American Medical Association. “The cumulative effect will place strain on the healthcare economy.”

    Last year, O'Sullivan and about 25 other clinicians sent a letter to the CEO of Vertex Pharmaceuticals, which manufactures Kalydeco, a drug that treats a subset of patients with cystic fibrosis, requesting that the company lower the price of the $295,000-a-year drug. Dr. Jeffrey Leiden, Vertex's president, CEO and chairman, met with some of the physicians and listened to their concerns. However, “nothing substantial happened,” O'Sullivan said. The drug, which was approved in January 2012, now costs $311,000 a year.

    Most manufacturers of pricey drugs provide patient-assistance programs. Kadcyla, a new oncology drug that treats patients with HER2-positive, late-stage breast cancer, costs about $94,000 for a roughly 10-month course of treatment. The company provides financial support to people who make less than $100,000 a year.

    About 80% of the drug pipeline has been developed by smaller companies, Cohen said. Experts expect orphan drugs to make up a larger portion of drug approvals during the next several years.

    Some traditional drug companies also have turned out targeted new drugs, with GlaxoSmithKline getting three orphan drugs approved by the FDA in fiscal 2013. On Oct. 1, Merck said it was shifting to a “more agile operating model,” sharply reducing costs to focus, in part, on developing drugs for unmet medical needs.

    In the JAMA article published this month, O'Sullivan wrote that drug companies should become more transparent about pricing. “A model of reduced profitability, particularly for lifelong therapies, is ethically responsible and institutionally plausible but will require pharmaceutical companies to develop new models and educate investors about the long-term advantage of regaining the trust of the public,” he wrote.

    Follow Jaimy Lee on Twitter: @MHjlee

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Oak Street Health
    Oak Street Health to expand into Arkansas, Iowa, Kansas, Virginia
    finance graphs hospital
    Primary care physicians' pay growth picked up in 2022: MGMA
    Most Popular
    1
    More healthcare organizations at risk of credit default, Moody's says
    2
    Centene fills out senior executive team with new president, COO
    3
    SCAN, CareOregon plan to merge into the HealthRight Group
    4
    Blue Cross Blue Shield of Michigan unveils big push that lets physicians take on risk, reap rewards
    5
    Bright Health weighs reverse stock split as delisting looms
    Sponsored Content
    Modern Healthcare A.M. Newsletter: Sign up to receive a comprehensive weekday morning newsletter designed for busy healthcare executives who need the latest and most important healthcare news and analysis.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Digital Health
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • ESG
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Opinion
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Hospital at Home
        • - Workplace of the Future
        • - Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • Data Center
      • Data Center Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • Newsletters
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Jobs
      • People on the Move
      • Reprints & Licensing